1

Case Report: Specific ABL-Inhibitor Imatinib Is an Effective Targeted Agent as the First Line Therapy to Treat B-Cell Acute Lymphoblastic Leukemia With a Cryptic NUP214::ABL1 Gene Fusion

rgjpcavrilq6v
Acute lymphoblastic leukemia (ALL) with recurrent genetic lesions. affecting a series of kinase genes. is associated with unfavorable prognosis. however. https://www.freaknleather.com/product-category/band-file/
Report this page

Comments

    HTML is allowed

Who Upvoted this Story